Use of bisphosphonates in skeletal metastasis

At present, there is sufficient evidence to propose practice guidelines that would include the use of bisphosphonates in the management of hypercalcemia, in breast cancer with bone metastases and multiple myeloma. Future research should concentrate on investigating the adjuvant use of bisphosphonates in breast cancer, particularly in order to find out the adequate target groups. Phase III studies comparing the old and new generation bisphosphonates are important as well as trials comparing the other palliative regimens with bisphosphonates. A widespread use of bisphosphonates would have a major impact on drug budgets. Does the cost of achieved palliation represent the optimal use of resources when compared with other possible options for palliation? This issue has not become easier with the emerging new expensive regimens in oncology. An economical analysis, ideally in the setting of randomized trials, is needed.